Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study

BACKGROUND: Programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors displayed considerable advantages in neoadjuvant therapy of non-small cell lung cancer (NSCLC), but the specific application of neoadjuvant immunotherapy has not been well determined, and the long-term prognostic data...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Fuqiang, Wu, Xiaoli, Wang, Xintian, Li, Kunkun, Wang, Yingjian, Shen, Cheng, Zhou, Jinghai, Niu, Huijun, Deng, Bo, Tan, Qunyou, Wang, Ruwen, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637677/
https://www.ncbi.nlm.nih.gov/pubmed/36353552
http://dx.doi.org/10.3389/fonc.2022.1022123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637677/
https://www.ncbi.nlm.nih.gov/pubmed/36353552
http://dx.doi.org/10.3389/fonc.2022.1022123

Ejemplares similares